Berotralstat hydrochloride is a Small Molecule owned by BioCryst Pharmaceuticals, and is involved in 21 clinical trials, of which 17 were completed, 3 are ongoing, and 1 is planned.
Berotralstat hydrochloride (BCX-7353) is a plasma kallikrein enzyme inhibitor. The unregulated conversion of kininogen to bradykinin (vasodilator) is responsible for the increase in vascular permeability, activation of inflammation and production of pain in the diseased state. The drug candidate by inhibiting the kallikrein blocks the conversion of kininogen to bradykinin. Thus by mediating the bradykinin associated acute swelling attacks in HAE, the drug shows the therapeutic intervention.
The revenue for Berotralstat hydrochloride is expected to reach a total of $12.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Berotralstat hydrochloride NPV Report.
Berotralstat hydrochloride is originated and owned by BioCryst Pharmaceuticals.
Berotralstat hydrochloride Overview
Berotralstat Hydrochloride (Orladeyo) is act as an anti-edmatous agent. It is formulated as hard gelatin capsules for oral route of administration. Orladeyo is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.
Berotralstat hydrochloride (BCX-7353) is under development for the treatment and prevention of acute hereditary angioedema (HAE). It is administered by oral route. The drug candidate is a second generation plasma kallikrein inhibitor.
BioCryst Pharmaceuticals Overview
BioCryst Pharmaceuticals (BioCryst) is a biotechnology company that designs, optimizes and develops small molecule drugs that block critical enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary angioedema. The company’s other pipeline products include, BCX9930, BCX9250 and galidesivir (BCX4430). It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through a process known as structure-guided drug design. BioCryst’s products include peramivir injections, which consist of Rapivab, Alpivab, Rapiacta, Orladeyo and Peramiflu for the treatment of Influenza. BioCryst is headquartered in Durham, North Carolina, the US.
The company reported revenues of (US Dollars) US$157.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$17.8 million in FY2020. The operating loss of the company was US$121.9 million in FY2021, compared to an operating loss of US$176.8 million in FY2020. The net loss of the company was US$184.1 million in FY2021, compared to a net loss of US$182.8 million in FY2020. The company reported revenues of US$75.8 million for the third quarter ended September 2022, an increase of 15.7% over the previous quarter.
Quick View – Berotralstat hydrochloride
|Highest Development Stage|